ArticlePloS one2015
Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 51 citations in OpenAlex.
- Tailoring virus-inspired nanoparticles for advanced drug and gene delivery.Materials today. Bio · 2026Review
- Comparison of plant- and mammalian cell-produced human papillomavirus pseudovirions.Journal of virological methods · 2025Article
- Molecular Analysis and Bioinformatics Assessment of Full-Length L1 Gene of Bovine Papillomavirus Type-1 as a Potential DNA Vaccine Study.Veterinary medicine international · 2025Article
- Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.Pharmaceutics · 2023Review
- Enhanced Immunogenicity of Adjuvanted Microparticulate HPV16 Vaccines Administered via the Transdermal Route.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Integrating plant molecular farming and materials research for next-generation vaccines.Nature reviews. Materials · 2022Review
- Microneedle systems for delivering nucleic acid drugs.Journal of pharmaceutical investigation · 2022Review
- A Comparative Study on Delivery of Externally Attached DNA by Papillomavirus VLPs and Pseudoviruses.Vaccines · 2021Article
- Transdermal drug delivery systems for fighting common viral infectious diseases.Drug delivery and translational research · 2021Review
- Transdermal Delivery of Chemotherapeutics: Strategies, Requirements, and Opportunities.Pharmaceutics · 2021Review
- Microarray patches enable the development of skin-targeted vaccines against COVID-19.Advanced drug delivery reviews · 2021Review
- Novel Production of Bovine Papillomavirus Pseudovirions in Tobacco Plants.Pathogens (Basel, Switzerland) · 2020Article
- Microneedle-Based Delivery: An Overview of Current Applications and Trends.Pharmaceutics · 2020Review
- The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization.Expert review of vaccines · 2020Review
- Microneedle Coating Methods: A Review with a Perspective.The Journal of pharmacology and experimental therapeutics · 2019Review
- Microneedle-based intradermal delivery of stabilized dengue virus.Bioengineering & translational medicine · 2019Article
- Advances in Designing and Developing Vaccines, Drugs and Therapeutic Approaches to Counter Human Papilloma Virus.Frontiers in immunology · 2018Review
- Article
- Local delivery of checkpoints antibodies.Human vaccines & immunotherapeutics · 2017Article
- The success of microneedle-mediated vaccine delivery into skin.Human vaccines & immunotherapeutics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Human papilloma virus-like particles (HPV VLP) serve as the basis of the current licensed vaccines for HPV. We have previously shown that encapsidation of DNA expressing the model antigen M/M2 from respiratory syncytial virus (RSV) in HPV pseudovirions (PsV) is immunogenic when delivered intravaginally. Because the HPV capsids confer tropism for basal epithelium, they represent attractive carriers for vaccination targeted to the skin using microneedles. In this study we asked: 1) whether HPV16 VLP administered by microneedles could induce protective immune responses to HPV16 and 2) whether HPV16 PsV-encapsidated plasmids delivered by microneedles could elicit immune responses to both HPV and the antigen delivered by the transgene. Mice immunized with HPV16 VLP coated microneedles generated robust neutralizing antibody responses and were protected from HPV16 challenge. Microneedle arrays coated with HPV16-M/M2 or HPV16-F protein (genes of RSV) were then tested and dose-dependent HPV and F-specific antibody responses were detected post-immunization, and M/M2-specific T-cell responses were detected post RSV challenge, respectively. HPV16 PsV-F immunized mice were fully protected from challenge with HPV16 PsV and had reduced RSV viral load in lung and nose upon intranasal RSV challenge. In summary, HPV16 PsV-encapsidated DNA delivered by microneedles induced neutralizing antibody responses against HPV and primed for antibody and T-cell responses to RSV antigens encoded by the encapsidated plasmids. Although the immunogenicity of the DNA component was just above the dose response threshold, the HPV-specific immunity was robust. Taken together, these data suggest microneedle delivery of lyophilized HPV PsV could provide a practical, thermostable combined vaccine approach that could be developed for clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.